Breast cancer Trials in Shanghai, China
Conditions / Breast cancer / Shanghai, China
Breast cancer has been the subject of sustained clinical investigation across multiple research sites.
314 total trials for this combination
Showing top 10 of 314 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06440018 | INSPIRE: a Multi-Cancer Early Detection Study | RECRUITING | — |
| NCT06103864 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | RECRUITING | — |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT06103864 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | RECRUITING | — |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | UNKNOWN | EARLY_PHASE1 |
| NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | RECRUITING | — |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | ACTIVE_NOT_RECRUITING | PHASE2 |